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Introduction: Management of sedation, analgesia, and anxiolysis are cornerstone therapies in the 
emergency department (ED). Dexmedetomidine (DEX), a central alpha-2 agonist, is increasingly 
being used, and intensive care unit (ICU) data demonstrate improved outcomes in patients 
with respiratory failure. However, there is a lack of ED-based data. We therefore sought to: 1) 
characterize ED DEX use; 2) describe the incidence of adverse events; and 3) explore factors 
associated with adverse events among patients receiving DEX in the ED.
Methods: This was a single-center, retrospective, cohort study of consecutive ED patients 
administered DEX (January 1, 2017–July 1, 2019) at an academic, tertiary care ED with an annual 
census of ~90,000 patient visits. All included patients (n= 103) were analyzed for characterization 
of DEX use in the ED. The primary outcome was a composite of adverse events, bradycardia and 
hypotension. Secondary clinical outcomes included ventilator-, ICU-, and hospital-free days, and 
hospital mortality. To examine for variables associated with adverse events, we used a multivariable 
logistic regression model.
Results: We report on 103 patients. Dexmedetomidine was most commonly given for acute 
respiratory failure, including sedation for mechanical ventilation (28.9%) and facilitation of non-
invasive ventilation (17.4%). Fifty-four (52.4%) patients experienced the composite adverse 
event, with hypotension occurring in 41 patients (39.8%) and bradycardia occurring in 18 patients 
(17.5%). Dexmedetomidine was stopped secondary to an adverse event in eight patients (7.8%). 
Duration of DEX use in the ED was associated with an increase adverse event risk (adjusted odds 
ratio, 1.004; 95% confidence interval, 1.001, 1.008).
Conclusion: Dexmedetomidine is most commonly administered in the ED for patients with acute 
respiratory failure. Adverse events are relatively common, yet DEX is discontinued comparatively 
infrequently due to adverse events. Our results suggest that DEX could be a viable option for 
analgesia, anxiolysis, and sedation in ED patients. [West J Emerg Med. 2021;22(5)1202–1209.]
INTRODUCTION 
The management of sedation, analgesia, and anxiolysis 
are critically important principles in the emergency department 
(ED). Dexmedetomidine (DEX) is a centrally acting and 
selective alpha-2 adrenoreceptor agonist, which inhibits 
norepinephrine release by binding to presynaptic alpha-2 
receptors. It provides sedation, anxiolysis, and analgesia via 
receptors in the brainstem and spinal cord.1,2 Furthermore, DEX 
does not cause respiratory depression, making it an attractive 
agent for the management of multiple patient populations. 
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What do we already know about this issue?
Dexmedetomidine (DEX) provides sedation, 
anxiolysis, and analgesia and is effective in various 
clinical situations. However, data is sparse from the 
emergency department (ED) domain.
What was the research question?
How is DEX used in the ED, and what is the 
incidence of adverse events associated with its use?
What was the major finding of the study?
Dexmedetomidine is used primarily in respiratory 
failure (46.3% of cases). While adverse events 
are common (52.4% of cases), they are of 
questionable clinical significance.
How does this improve population health?
The use of dexmedetomidine could be an 
important adjunct in the care of multiple patient 
cohorts in the ED. 
In patients with acute respiratory failure, data from 
mechanically ventilated intensive care unit (ICU) patients have 
demonstrated improved outcomes with DEX, when compared to 
benzodiazepines, including a reduction in delirium and ventilator 
duration.2-4 In ICU patients who cannot tolerate non-invasive 
positive pressure ventilation (NIPPV), DEX has been shown 
to be effective at facilitating NIPPV and may be associated 
with improved outcomes (ie, reduced intubation rates and ICU 
length of stay).1,5 However, there is a lack of data from the ED 
domain regarding DEX use in patients with acute respiratory 
failure. Other descriptions of DEX use in the ED include alcohol 
withdrawal and procedural sedation. Although the data are 
limited, a few studies have shown that DEX may reduce the need 
for endotracheal intubation in patients with alcohol withdrawal, 
and be a safe and effective procedural sedation agent.6-9
Given the lack of data and trials regarding DEX use 
in the ED, there is a significant knowledge gap and lack of 
familiarity regarding the use of this agent. Furthermore, as 
DEX has consistently been shown to increase the incidence 
of hypotension and bradycardia, its safety profile in the ED 
during routine use is unknown as well. We conducted this 
study with several objectives in mind: 1) to characterize the 
use of DEX in the ED; 2) describe the incidence of adverse 
events in the ED population; and 3) explore factors associated 
with adverse events among patients receiving DEX in the ED.
METHODS
Study Design
This was a single-center, retrospective, cohort study and is 
reported in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement 
(see supplemental Table S1).10 The study was approved 
by the Human Research Protection Office at the principal 
investigator’s institution with waiver of informed consent. 
There was no financial support or funding organization 
associated with the study. 
Study Setting and Population
The study was conducted at an academic, university-
affiliated teaching hospital with an annual ED census of 
approximately 90,000 patient visits. Given the clinical outcome 
data regarding DEX, an order-set and protocol was introduced 
in the ED in 2017. This protocol advocated for a static DEX 
dose of 0.4 micrograms/kilogram/hour (mcg/kg/hour) in non-
intubated patients. In mechanically ventilated patients, the 
protocol advocated for a starting dose of 0.7 mcg/kg/hour, with 
a recommended titration of 0.1 mcg/kg/hour every 45 minutes, 
up to a maximum dose of 1.5 mcg/kg/hour. Titration was by 
physician order, and not titratable by the nurse. Bolus doses of 
DEX were not recommended by the protocol, nor given during 
the study period. Over a 30-month period (January 1, 2017–July 
1, 2019), all consecutive patients with an order to receive DEX 
were identified via electronic health record (EHR) query and 
were eligible for inclusion. Inclusion criteria were 1) age ≥ 18 
years; and 2) the receipt of DEX in the ED for any indication. 
Study Protocol  
Participant Selection and Data Collection
We identified patients with an order for DEX as receiving 
DEX in the ED by registry query, which was verified by 
review of the EHR. We excluded patients who did not 
actually receive DEX , as well as duplicate patients in the 
registry. All measurement and clinical data were gathered 
from the EHR using a standardized data collection form 
(created a priori), collated into an Excel 2016 (Microsoft 
Corporation, Redmond, WA, 2016) data management file, 
and exported to SPSS version 26, 2019 (IBM Corporation, 
Armonk, NY,) for management and data analysis. Prior 
to analysis, we checked the database for out-of-range and 
implausible values, and rechecked data as needed in the EHR 
to ensure accuracy. Baseline characteristics included the 
following: age; gender; race; body mass index; pre-existing 
comorbid conditions; disposition data; initial vital signs in 
the ED; and select laboratory values. Comorbid conditions 
were dementia, diabetes mellitus, cirrhosis, heart failure, 
end-stage renal disease, chronic obstructive pulmonary 
disease, immunosuppression, malignancy, alcohol abuse, and 
psychiatric illness (ie, schizophrenia, bipolar disorder, major 
depression, or generalized anxiety disorder). Laboratory 
values included lactate, creatinine, bilirubin, platelets, 
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hemoglobin, and blood gases. The ED process of care 
variables included length of stay, vasopressor use, and need 
for mechanical ventilation.
We collected all DEX-related data in the ED including the 
following: indication for its use (per clinician documentation 
in the ED); time from ED arrival to order and time from order 
to drug administration; duration of use in the ED; dosing; and 
mental status (Richmond Agitation-Sedation Scale [RASS[ 
or Glasgow Coma Scale [GCS] at initiation. Additionally, we 
collected vital signs at initiation and their lowest values during 
drug infusion, and the number of patients in whom DEX was 
stopped in the ED, as well as co-administered analgesics and 
sedatives in the ED. 
We collected details on adverse events and the treatment 
variables surrounding adverse events. The primary adverse events 
of interest included the incidence of hypotension and bradycardia. 
Similar to a prior large, randomized trial, hypotension was 
defined as a systolic blood pressure <80 millimeters mercury 
(mm Hg), a diastolic blood pressure <50 mm Hg, or > 30% 
decrease from baseline (systolic, diastolic, or mean arterial 
pressure).3 Bradycardia was also defined based on prior trials, and 
included a heart rate < 40 beats per minute, < 60 beats per minute, 
or > 30% decrease from baseline.3,4 We also collected data 
regarding the need for vasoactive medications or fluid boluses 
after DEX initiation. If vasoactive medications or fluid boluses 
were given prior to DEX inititation, this was not counted as event 
secondary to DEX use. Finally, the cessation of DEX due to an 
adverse event was obtained from clinician documentation, and 
determined in the following manner: cessation due to hypotension 
and/or bradycardia, as defined in adverse events; or if cessation 
occurred due to inadvertent extubation.
An a priori subgroup of interest were the patients 
requiring mechanical ventilation in the ED.
Outcomes
We analyzed all included patients for characterization 
of DEX in the ED. The primary outcome of interest was the 
incidence of hypotension and bradycardia related to DEX use. 
Other clinical outcomes of interest included the incidence 
of acute brain dysfunction on ICU day 1 (delirium and 
coma), ventilator-, ICU- and hospital-free days, and hospital 
mortality. Coma was defined as having a RASS of -4 or -5 for 
every measurement while in the ICU. “Free” days account 
for both time (ie, duration of ventilation or lengths of stay) 
and mortality and are indexed to study day 28. In participants 
who survived 28 days, “-free” days are defined as 28 minus 
duration of ventilation (ventilator-free days) or length of 
stay (ICU- and hospital-free days). Participants who did not 
survive 28 days were assigned zero “-free” days. 
Analysis
Patient characteristics are reported using descriptive 
statistics, including mean (standard deviation [SD]) 
and median (interquartile range [IQR]), and frequency 
distributions. We compared continuous variables using 
independent samples t-test or Mann-Whitney U test, whereas 
categorical variables were compared using chi-square test or 
Fisher’s exact test. We assessed the normality of the data by 
inspection of Q-Q plots and the Kolmogorov-Smirnov test. 
For the purposes of this analysis, the primary outcome 
of adverse events was a composite outcome of hypotension 
or bradycardia. To examine for potential variables associated 
with adverse events we used a multivariable logistic regression 
model. In anticipation of a small number of events, we chose 
a parsimonious model and followed recommendations to 
select covariates a priori.11 We therefore selected the following 
predictors for the model: 1) vasopressor infusion in the ED; 
2) DEX duration in the ED; 3) heart rate at initiation of DEX; 
and 4) mechanical ventilation use in the ED. These variables 
were chosen for the following reasons: 1) Patients in shock 
may be more prone to experience hypotension related to DEX 
use; 2) a longer duration of use would allow greater time for 
adverse events to occur; 3) a lower baseline heart rate may 
lead to a higher incidence of bradycardia; and 4) mechanically 
ventilated patients are sicker and typically require more 
sedation than non-intubated patients, therefore predisposing 
them to a higher complication rate. 
All tests were two-tailed with an alpha of 0.05 for statistical 
significance. As the study design is a retrospective cohort study 
over a fixed time frame, the sample size was limited to the 
number of patients receiving DEX during the course of routine 
care in the ED. Based on randomized trials examining DEX use 
in mechanically ventilated patients, we expected an adverse event 
rate ranging anywhere from 20-50%.2-4 Assuming an estimated 
event (ie, composite adverse event) per covariable ratio of 10:1 
necessary for multivariable logistic modeling, we assumed a 
sample size of 100 patients would be adequate to describe DEX 
use in the ED and explore factors associated with adverse events, 
in a hypothesis-generating multivariable model.12,13
RESULTS
A total of 103 patients were included in the study, and 
Figure 1 shows the study flow and final study population. 
Baseline characteristics are reported in Table 1. There was a 
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No adverse event 
(n = 54)
Adverse event 
(n = 49) P
Age (years) 54 (37-65) 55 (42-65) 54 (35-65) 0.692
Female, n (%) 39 (32.2) 23 (42.6) 16 (32.7) 0.299
BMI 27.0 (22.4-35.0) 29.1 (23.8-35.0) 25.1 (21.1-35.8) 0.248
Race, n (%) 
Black 52 (43.0) 27 (50.0) 25 (51.0) 0.918
White 51 (42.1) 27 (50.0) 24 (49.0)
Comorbidities, n (%) 
Dementia 3 (2.5) 1 (1.9) 2 (4.1) 0.502
Diabetes mellitus 31 (25.6) 17 (31.5) 14 (28.6) 0.748
Cirrhosis 7 (5.8) 4 (7.4) 3 (6.1) 0.796
Heart failure 16 (13.2) 10 (18.5) 6 (12.2) 0.380
ESRD 5 (4.9) 4 (7.4) 1 (2.0) 0.206
COPD 22 (18.2) 14 (25.9) 8 (16.3) 0.235
Alcohol abuse 27 (22.3) 16 (29.6) 11 (22.4) 0.408
Illicit drug abuse 29 (24.0) 17 (31.5) 12 (24.5) 0.431
Psychiatrica 16  (13.2) 6 (11.1) 10 (20.4) 0.193
Disposition Data, n (%)
Admit Location 0.472
ICU 97 (80.2) 50 (92.6) 47 (95.9)
Floor 6 (5.0) 4 (7.4) 2 (4.1)
Temperature (oC) 36.7 (36.4-37.1) 36.6 (36.3-37.0) 36.7 (36.5-37.2) 0.164
Heart rate (bpm) 107 (23) 104 (23) 109 (22) 0.249
Respiratory Rate (bpm) 23 (7) 23 (7) 23 (7) 0.684
Systolic pressure (mm Hg) 145 (30) 143 (26) 146 (33) 0.646
Diastolic pressure (mm Hg) 89 (22) 89 (21) 88 (23) 0.848
Peripheral oxygen saturation (%) 94 (8) 96 (50) 93 (10) 0.018
Lactate (mmol/L) 2.3 (1.4-3.6) 2.3 (1.4-3.5) 2.2 (1.3-4.7) 0.900
Creatinine (mg/dL) 1.0 (0.8-1.3) 1.1 (0.8-1.3) 1.0 (0.7-1.2) 0.289
Bilirubin (mg/dL) 0.4 (0.3-0.6) 0.4 (0.3-0.6) 0.4 (0.3-0.8) 0.616
pH (n = 78) 7.31 (0.13) 7.31 (0.11) 7.30 (0.14) 0.560
Partial pressure arterial oxygen (n=34) 150 (76) 144 (61) 157 (93) 0.628
Partial pressure arterial or venous carbon dioxide 
(n = 78)
48 (17) 45 (11) 52 (21) 0.086
SOFA score 1.0 (0-4.0) 1.0 (0-3.0) 1.0 (1.0-4.0) 0.697
ED process of care variables
Length of stay (hours) 7.1 (4.7-9.6) 6.7 (4.5-8.7) 7.9 (5.2-10.3) 0.101
Vasopressor infusion, n (%) 14 (11.6) 4 (7.4) 10 (20.4) 0.055
Mechanically ventilated, n (%) 40 (33.1) 24 (44.4) 16 (32.7) 0.220
Table 1. Characteristics of included study participants.
aPsychiatric if diagnosed with schizophrenia, bipolar, major depression, or generalized anxiety disorder
Continuous variables are reported as mean (standard deviation) and median (interquartile range).
BMI, body mass index; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; 
C, Centigrade; bpm, beats per minute; bpm, breaths per minute; mm Hg, millimeters mercury; mmol/L, millimoles per liter; mg/dL, 
milligrams per deciliter; SOFA, sequential organ failure assessment; ED, emergency department.
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Variable
All subjects
(n  = 103)
No adverse event 
(n = 54)
Adverse event 
(n = 49) P
Indication for dexmedetomidine, n (%)* 0.847
Procedural sedation 4 (3.3) 2 (3.7) 2 (4.1)
Alcohol withdrawal 9 (7.4) 5 (9.3) 4 (8.2)
Anxiolysis 14 (11.6) 5 (9.3) 9 (18.4)
Psychosis/agitation 18 (14.9) 10 (18.5) 8 (16.3)
Facilitation of NIPPV 21 (17.4) 10 (18.5) 11 (2.4)
Sedation for mechanical ventilation 35 (28.9) 21 (38.9) 14 (28.6)
Other 2 (1.7) 1 (1.9) 1 (2.0)
Time from ED arrival to order 
(minutes)
156 (64 – 317) 170 (73 – 317) 136 (42 – 333) 0.722
Time from order to administration 
(minutes)
26 (11 – 55) 42 (16 – 60) 21 (9 – 32) 0.021
Duration of dexmedetomidine in ED 
(minutes)
139 (74 – 211) 122 (69 – 207) 164 (96 – 240) 0.041
Starting dose in ED (mcg/kg/hour) 0.4 (0.2 – 0.4) 0.4 (0.2 – 0.5) 0.4 (0.2 – 0.4) 0.267
RASS at initiation of 
dexmedetomidine (n= 29)
1 (0 – 3) 1 (-1 to 3) 1 (0 - 2) 0.811
GCS at initiation of dexmedetomidine 
(n= 40)
13 (10 – 15) 13 (11 – 15) 13 (9 – 14) 0.366
Co-administered analgesics and 
sedatives, n (%)
0.248
Fentanyl 41 (39.8) 23 (42.6) 18 (36.7)
Propofol 28 (27.2) 16 (29.6) 12 (24.5)
Midazolam 34 (33.0) 17 (31.5) 17 (34.7)
Ketamine 38 (36.9) 18 (33.3) 20 (40.8)
Lorazepam 32 (31.1) 15 (27.8) 17 (34.7)
Haloperidol 25 (24.3) 14 (25.9) 11 (22.4)




















Heart rate (bpm) 105 (23) 86 (21) 102 (21) 91 (22) 108 (25) 81 (19) 0.163 0.010
Respiratory rate (bpm) 23 (7) 20 (18) 24 (7) 20 (6) 23 (7) 18 (5) 0.697 0.051
Systolic blood pressure (mm Hg) 140 (29) 112 (25) 141 (27) 124 (21) 138 (32) 99 (22) 0.606 <0.001
Diastolic blood pressure (mm Hg) 85 (24) 68 (18) 86 (20) 77 (16) 84 (27) 58 (16) 0.740 <0.001
Mean arterial pressure (mm Hg) 101 (24) 82 (19) 102 (21) 92 (16) 100 (27) 71 (16) 0.796 <0.001
Dexmedetomidine infusion stopped 
in ED, n (%)a
22 (18.2) 11 (20.4) 11 (22.4) 0.797
aEighteen patients were documented as having an additional secondary indication for dexmedetomidine use.
NIPPV, non-invasive positive pressure ventilation; ED, emergency department; mcg/kg/hour, micrograms/kilogram/hour; RASS, Richmond 
Agitation-Sedation Scale; GCS, Glasgow Coma Scale; bpm, beats per minute; bpm, breaths per minute; mm Hg, millimeters mercury.
Table 2. Dexmedetomidine dosing and sedation characteristics.
statistical difference in peripheral oxygen saturation (mean 
[SD]) between patients experiencing an adverse event vs those 
who did not (93 [10] vs 96 [50], P = 0.018]. There were no 
other significant differences between patients experiencing an 
adverse event vs those who did not.
Dexmedetomidine-related variables are shown in Table 
2. Acute respiratory failure, including mechanical ventilation 
(28.9%) and NIPPV (17.4%), was the most common 
indication for DEX, followed by control of agitation (14.9%) 
and anxiety (11.6%). The median starting dose in the ED 
was 0.4 mcg/kg/hour (0.2 – 0.4). However, variability in 
starting dose did exist, as 16 patients were started at a dose 
of 0.7 mcg/kg/hour or higher (3 patients ≥ 1.0 mcg/kg/hour). 
Median infusion rate remained at 0.4 mcg/kg/hour for the 
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first four hours, and the highest median infusion rate was 0.7 
(0.4 – 0.9), demonstrating that, overall, relatively low doses 
of DEX were used in the ED. Dexmedetomidine was stopped 
in the ED in 22 (18.2%) patients. Co-administered analgesics 
and sedatives included fentanyl (39.8%); ketamine (36.9%); 
midazolam (33%); lorazepam (31.1%); haloperidol (28.2%); 
and propofol (27.2%).
Adverse events and clinical outcomes are reported in 
Table 3. Fifty-four (52.4%) patients experienced the composite 
adverse event, with hypotension occurring in 41 patients 
Variable All subjects (n = 103)
Hypotension, n (%) 41 (39.8)
SBP <80 mm Hg 8 (7.8)
DBP <50 mm Hg 14 (13.6)
>30% decrease from baseline* 19 (18.4)
Bradycardia, n (%)*
<60 bpm 18 (17.5)
<40 bpm 0 (0.0)
Vasoactive medication given after 
dexmedetomidine initiated, n (%)
8 (7.8)
Fluid bolus given after 
dexmedetomidine initiation, n (%)
12 (11.7)
Cessation of dexmedetomidine due to 
adverse event, n (%)
8 (7.8)
Starting dose in ED (mcg/kg/hour) 0.4 (0.2 – 0.4)




ICU-free days** 21.5 (8.2)
Hospital-free days 18.0 (8.4)
Hospital mortality, n (%) 10 (9.7)
*Refers to a decrease in systolic, diastolic, or mean arterial 
pressure. 
**Refers to the 97 patients admitted to the intensive care unit from 
the emergency department.
Continuous variables are reported as mean (standard deviation) 
and median (interquartile range).
SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, 
beats per minute; ED, emergency department; mcg/kg/hour, 
micrograms/kilogram/hour; ICU, intensive care unit.
Table 3. Adverse events and clinical outcomes.
(39.8%) and bradycardia occurring in 18 patients (17.5%). 
Patients experiencing an adverse event were given a fluid bolus 
(20.4% vs 3.7%, P <0.01) and vasoactive medications (12.2% 
vs 3.7%, P = 0.11) more frequently when compared to patients 
without an adverse event. Dexmedetomidine was stopped 
secondary to an adverse event in eight patients (7.8%). Clinical 
outcomes for patients experiencing an adverse event vs those in 
patients with no adverse event (mean [SD]), were as follows: 
ventilator-free days, (20.4 [10.5] vs 22.6 [8.7], P = 0.44); ICU-
free days, (21.7 [8.1] vs 21.3 [8.4], P = 0.83),; and hospital-
free days (18.5 [8.1] vs 17.5 [8.7], P = 0.53). Mortality among 
patients experiencing an adverse event when compared to those 
with no adverse event was 10.2% vs 9.3%, P = 0.87.
Table 4 shows the multivariable logistic regression analysis 
for predictors of the composite primary outcome. Duration of 
DEX use in the ED was associated with an increased risk for 
hypotension or bradycardia (adjusted odds ratio [aOR], 1.004; 
95% CI, 1.001, 1.008), while vasopressor infusion in the ED was 
associated with a decrease risk (aOR, 0.21; 95% CI, 0.05, 0.82).




infusion in the ED 




duration in the ED
1.004 1.001 – 
1.008
0.01 0.022
Heart rate at 
initiation of 
dexmedetomidine




ventilation in the ED
1.63 0.60 – 
4.40
0.51 0.341
Table 4. Multivariable logistic regression analysis with a composite 
of hypotension and bradycardia as the dependent variable.
ED, emergency department; aOR, adjusted odds ratio; CI, 
confidence interval.
Details regarding the mechanically ventilated subgroup 
are provided in supplemental tables S2-4. Overall, the dosing 
characteristics and adverse events experienced by mechanically 
ventilated patients were similar to the entire cohort. 
DISCUSSION
As sedation and pain control are cornerstone therapies 
provided in the ED, and with the increase in use of DEX, 
information regarding its use in the ED is critical before 
quality improvement or future research can occur. The current 
study provides some new information regarding DEX use in 
the ED and builds on prior work by examining this agent in 
the ED domain. 
With respect to our first objective, DEX is used for 
diverse indications in the ED, and most commonly for 
patients with respiratory failure. This is congruent with 
prior work and facilitated by DEX’s analgesic and sedative 
properties, without suppression of respiratory drive. The co-
administration of other sedatives and analgesics was common, 
and could be driven by the known limitations of DEX, such 
as slower onset of action. There was a delay in administration 
of DEX (156 minutes) and relatively static dosing in the ED. 
This is likely driven by the lack of DEX in the ED (ie, ordered 
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from pharmacy), as well as the institutional protocol, which 
called for no titration (in non-intubated patients) or physician-
ordered titration (in mechanically ventilated patients). 
Going forward, areas for potential improvement could be as 
follows: 1) earlier identification of patients who may benefit 
from DEX, given the 2.5 hours of elapsed time from patient 
arrival to order; and 2) titrated dosing if DEX is tolerated, yet 
sedation goals have not been achieved. 
Our most important finding relates to the adverse events 
experienced by ED patients given DEX. Prior work in difficult-
to-sedate patients (n = 13) stated that DEX “is not safe in 
the ED setting.”14 Our results would suggest otherwise, and 
demonstrate that an ED-based DEX protocol can be effectively 
implemented. While adverse events were relatively common, 
the event rate for DEX use is congruent with that experienced 
in large randomized trials.2-4 Also, when placed in the context 
of the reported incidence of hypotension with midazolam 
(11.6% to 55.7%) and propofol (13.4% to 52.4%) described in 
the literature, our results further suggest that DEX compares 
favorably in the ED setting.3,15,16 Furthermore, in only eight 
patients (7.8%) did physicians stop DEX due to an adverse 
event, suggesting that while hypotension and bradycardia 
were relatively common, these events were clinically well 
tolerated as judged by the treating team. Patients experiencing 
adverse events did require more intensive therapy in the ED, as 
demonstrated by the administration of more fluid boluses and 
vasoactive medications. 
There was no statistical difference in patient-centered 
clinical outcomes between patients experiencing an adverse 
event when compared to those who did not. However, we 
urge caution in interpreting these clinical outcome data, given 
the small sample size. Contrary to our rationale for including 
vasopressors in the multivariable model, vasopressor infusion in 
the ED was associated with a lower chance for adverse events. It 
is possible that vasopressor titration reduced the risk of reported 
hypotension. While our study lacks granular detail on pressor 
requirements during DEX infusion, this finding is congruent with 
prior work showing that DEX is well tolerated in patients with 
shock.17A potentially important finding is the fact that duration 
of DEX exposure in the ED was associated with adverse events. 
While we lack specific detail on the exact timing of events, these 
data suggest the need for ongoing diligent monitoring for safety 
while DEX is being used in the ED. 
Finally, in our subgroup of mechanically ventilated 
patients, the dosing of DEX and adverse events were 
comparable to non-intubated patients. While no definitive 
conclusions can be drawn from this small sample size, our 
findings suggest that DEX use in the ED could be a viable 
option going forward. 
LIMITATIONS
This study has several limitations. This was a 
retrospective, single-center study that carries with it all of 
the limitations of that design, including limits with respect to 
generalizing these results to other centers, especially those 
where DEX use is infrequent in both the ED and ICU. While 
to our knowledge this is the largest ED-based DEX study to 
date, the small sample size limits any conclusions that can be 
drawn from these data. We further emphasize that point with 
respect to the subanalysis with an even smaller sample size 
and commensurate power limitations secondary to that. Due 
to an overall lack of sedation depth documentation, we cannot 
comment on the efficacy of DEX use in the ED. Future studies 
will need to assess for sedation depth, pain control, and 
anxiolysis in a much more granular fashion. 
We defined our adverse events based on prior work from 
randomized trials on DEX in mechanically ventilated patients. 
While our adverse event rate was congruent with prior work, 
had our definition differed, the incidence of hypotension and 
bradycardia experienced in the ED could be lower than our 
current definition. This is especially important when considering 
that only eight patients had their DEX infusion stopped because 
of an adverse event. We also do not have details on why DEX 
was stopped outside of adverse events. It is possible that 
DEX was stopped because of inefficacy, or improving clinical 
trajectory. Due to the study design, it is impossible to ascribe 
causation for the adverse events, as multiple agents were used 
in addition to DEX, and we can only describe associations. 
Finally, due to the overall low event rate and small sample size, 
the results of our multivariable model should be considered 
exploratory and hypothesis-generating at this point. 
CONCLUSION
Dexmedetomidine is most commonly administered 
in the ED for patients with acute respiratory failure 
(ie, those requiring mechanical ventilation or NIPPV). 
While adverse events are relatively common, they are of  
questionable clinical significance. Our results suggest that 
dexmedetomidine can be incorporated effectively into clinical 
care in the ED and be a viable option for analgesia, anxiolysis, 
and sedation in ED patients, similar to its role in the ICU.
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